What to Know About This Mineralys Insider Sale Before a December FDA Date
Insider divested 2% of direct holdings via pre-planned Rule 10b5-1 trading arrangement, following a 90% stock surge over the past year.
Overview
Chief Executive Officer Jon Congleton reported a sale of 10,700 shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) on July 13, 2026, according to an SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average sale price ($27.24); post-transaction value based on July 13, 2026 market close ($27.59).
Details
Mineralys Therapeutics is a clinical-stage biopharmaceutical company with a market capitalization of $2 billion, currently advancing investigational therapies for cardiovascular disease management. The company operates with a lean operational footprint while maintaining focus on its lead candidate, lorundrostat, which addresses an underserved patient population with resistant hypertension. As a pre-revenue clinical entity, Mineralys is positioned within the high-risk, high-reward segment of the biotechnology sector, with value creation contingent upon successful clinical development and regulatory approval of its pipeline assets.
Source
Originally published at www.fool.com.